5-((N-methylpiperazine)methyl)furfural

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-((N-methylpiperazine)methyl)furfural
• 英文别名: 5-((4-methylpiperazine-1-yl)methyl)furan-2-carboxaldehyde；5-((4-Methylpiperazine-1-yl)methyl)furan-2-carboxaldehyde；5-[(4-methylpiperazin-1-yl)methyl]furan-2-carbaldehyde
• 化学式: C₁₁H₁₆N₂O₂
• 分子量: 208.26
• InChiKey: AEEAPDKDGYEYHT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (5R,5aR,8aS,9S)-9-amino-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one 、 5-((N-methylpiperazine)methyl)furfural 在 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 12.0h， 生成
  参考文献：
  名称：

  Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents

  摘要：

  Cancer multidrug resistance (MDR) is a common cause of treatment failure in cancer patients. Increased expression of permeability glycoprotein (P-gp), which is also known as MDR-1, is the main cause of multidrug resistance. Podophyllotoxin derivatives hold great promise in the battle to overcome multidrug resistance, as they can induce cytotoxicity through multiple mechanisms. Here, we synthesized sixteen novel podophyllotoxin derivatives and evaluated their cytotoxicities in human cancer cell lines, HeLa, 1(562 and K562/A02. Some of these compounds were more potent than etoposide, a clinically relevant inhibitor of DNA repair enzymes. In particular, compound 5p exhibited the most potent activity toward drug-resistant K562/A02 cells, as it robustly inhibited tumor cell proliferation and induced apoptosis. Furthermore, preliminary investigation suggested that 5p inhibited the expression of MDR-1 in K562/A02 cells more effectively than etoposide. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.08.006
• 作为产物：
  描述：

  5-((N-methylpiperazine)methyl)furfuryl alcohol 在 manganese(IV) oxide 作用下， 以 丙酮 为溶剂， 反应 4.0h， 以80%的产率得到5-((N-methylpiperazine)methyl)furfural
  参考文献：
  名称：

  4β-氮取代呋喃叔胺类鬼臼毒素衍生物及其制 备方法与应用

  摘要：

  本发明提供了一种4β-氮取代呋喃叔胺类鬼臼毒素衍生物，其结构通式为：该化合物溶解性好，抗肿瘤活性强，特别是对肺癌、恶性淋巴瘤、急性白血病等肿瘤细胞具有明显抑制作用；本发明还提供了该化合物的制备方法。

  公开号：

  CN103804388B

文献信息

• [EN] PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE COMME AGENT ANTICANCER
  申请人：PF MEDICAMENT

  公开号：WO2011045344A1

  公开（公告）日：2011-04-21

  The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent.

  本发明涉及具有以下通式(I)的化合物：(公式I)以及它们的药用可接受盐、它们的制备方法及其用途，尤其是作为抗癌剂。
• Synthesis of 2-imidazolidinylidene propanedinitrile derivatives as stimulators of gastrointestinal motility. 1
  作者：Setsuya Sasho、Hiroyuki Obase、Shunji Ichikawa、Takio Kitazawa、Hiromi Nonaka、Rika Yoshizaki、Akio Ishii、Katsuichi Shuto

  DOI：10.1021/jm00057a007

  日期：1993.3

  Ranitidine (1), the histamine H2-receptor antagonist, has been previously reported to increase gastric emptying and gastric motility by inhibition of acetylcholinesterase (AChE) and enhancement of acetylcholine (ACh) release. In order to obtain potent gastroprokinetic agents, a new series of ranitidine derivatives (5-32) possessing a nitrogen atom instead of a sulfur atom (B) was synthesized and their

  雷尼替丁（1），一种组胺H2受体拮抗剂，先前已报道通过抑制乙酰胆碱酯酶（AChE）和增强乙酰胆碱（ACh）释放来增加胃排空和胃动力。为了获得有效的胃肠动力药物，合成了一系列新的雷尼替丁衍生物（5-32），其中的雷尼替丁衍生物具有一个氮原子而不是一个硫原子（B），并且它们的AChE抑制活性和对豚鼠回肠电诱发收缩的增强作用已得到证实。评估。取代基R1和R2的改性显着影响了活性。特别是，化合物19（（1- [2-[[[5-（哌啶子基甲基-2--2-呋喃基]甲基]氨基]-乙基] -2-咪唑啉亚基）丙酸酯富马酸酯显示出更强的AChE抑制活性20到100倍对回肠收缩有增强作用 分别比雷尼替丁。此外，化合物19（KW-5092）增强了麻醉兔子的肠胃蠕动，并具有可忽略的组胺H2受体阻断活性。
• PYRAZOLOPYRIDINE DERIVATIVES AS ANTICANCER AGENT
  申请人：Bedjeguelal Karim

  公开号：US20120245170A1

  公开（公告）日：2012-09-27

  The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent.

  本发明涉及以下一般式(I)的化合物：(I)及其药学上可接受的盐，其制备方法以及它们的用途，尤其是作为抗癌剂。
• Pyrazolopyridine derivatives as anticancer agent
  申请人：Bedjeguelal Karim

  公开号：US08889711B2

  公开（公告）日：2014-11-18

  The present invention concerns compounds of following general formula (I): (Formula I) and their pharmaceutically acceptable salts, their method of preparation and their uses, notably as anticancer agent.

  本发明涉及以下通式（I）的化合物：（通式I），以及它们的药学上可接受的盐、制备方法和用途，特别是作为抗癌剂。
• US8889711B2
  申请人：——

  公开号：US8889711B2

  公开（公告）日：2014-11-18